Kiniksa Pharmaceuticals (NASDAQ:KNSA) Coverage Initiated at Citigroup
Citigroup began coverage on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA – Free Report) in a report issued on Thursday morning, Marketbeat reports. The firm issued a buy rating and a $40.00 price objective on the stock. Separately, Wedbush reiterated an “outperform” rating and set a $34.00 price target on shares of Kiniksa Pharmaceuticals in a report […]
